Effect of JAK1/2 inhibition on High-Output Heart Failure Associated With Myeloproliferative Disease

Fujii, Yuki; Takei, Makoto; Hayashi, R.; Yagi, Ryuichiro; Kawano, Megumi; Endo, Akinori; Suzuki, Kenji; Hirata, Naoki; Hasegawa, Tasuku; Takahashi, Toshiyuki

doi:10.1016/j.jaccao.2020.02.018

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were ≥ 18 years of age with palpable splenomegaly ≥ 5 cm below the left costal margin and a confirmed diagnosis of primary MF (WHO criteria) or post-polycythemia vera or post-essential thrombocythemia MF (International Working Group for Myelofibrosis Research and Treatment [IWG-MRT] criteria) (Fujii et al 2020).…”

Section: Inclusion Criteriamentioning

confidence: 99%

Expression of CD4<sup>+</sup>T Cells in Myeloproliferative Diseases and the Effect of Ruxolitinib Treatment on Prognosis

Song,

Dong,

Yang

et al. 2024

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Myeloproliferative disorders (MPDs) are rare diseases in which the bone marrow produces too many red, white, or platelets. Myeloproliferative disorders are neither acute nor leukaemia. To study ruxolitinib's effect on MPD therapy and CD4 + T cell expression. In total, 66 JAK2V617F-positive MPD patients were admitted to our hospital. The patients were randomly assigned to control and research groups (each 33). Hydroxyurea pills were given to the control group and ruxolitinib to the observation group. The MPN-10 assesses 10 of the most clinically relevant symptoms, including fatigue and generates a Total Symptom Score (TSS). In addition, by comparing myelofibrosis (MF), spleen length, JAK2V617F gene expression, peripheral blood lymphocyte and T cell levels, and prognostic levels, analyze the shortcomings of each group. Post-treatment, MPN-10, MF, and spleen length diameter were reduced in both groups (P<0.05), with the study group showing a higher reduction than the control group (P<0.05).Compared to prior treatment, JAK2V617F gene expression was reduced in all groups after 6 months and a year of medication. The study category had a higher decrease in expression than the control group. After therapy, CD4 and CD4/CD8 levels rose, but CD8 and Treg levels decreased. The study group had increased CD4 and CD4/CD8 levels, whereas the control group had lower CD8 and Treg levels. The study group had a greater 1-year survival rate than the control group, but the control group had lower mortality and adverse event rates. In JAK2V617F-positive MPD patients, ruxolitinib reduces JAK2V617F gene expression, myelofibrosis, and therapeutic impact.

show abstract

Section: Inclusion Criteriamentioning

confidence: 99%